Q-omics provides the consensus-scored SNORD91A profile across patient tissues and cancer cell-line models. SNORD91A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNORD91A is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, SNORD91A RNA expression shows 12,847 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRP, and LSCC as cancer lineages where SNORD91A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD91A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD91A survival associations across molecular data types. SNORD91A RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD91A RNA expression–survival associations across cancer types. High SNORD91A expression shows unfavorable associations in KIRC, KICH, LGG, KIRP and COAD, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNORD91A RNA expression.
This table summarizes SNORD91A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD91A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD91A shows higher tumor expression in KIRP, READ, LUSC, STAD, KIRC and LUAD. The KIRP box plot shows higher SNORD91A RNA expression in tumor versus normal tissue (log2 FC = +0.292, t-test p = .014).
This table shows molecular features associated with SNORD91A in patient tissues and cancer cell lines. In patient samples, SNORD91A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
